Ulixe Corp sells Ulixe Nova S.r.l. for €1.00; restructuring ahead of Nasdaq uplisting

ULIXE CORP.

Sold 100% equity in Ulixe Nova to Condotti Capital S.r.l. for nominal €1.00 on June 18, 2026.
Divestiture driven by Ulixe Nova's financial constraints and capital needs; part of strategic reorganization.
Post-sale structure: Ulixe Italy owns Dale Consulting, Ulixe Pharma, MBSNet; MBSNet owns Fintexa.
Ulixe Corp previously acquired MBSNet (Nov 2025) to enhance fintech and digital payments capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.